Literature DB >> 21233143

Seizure recurrence after antiepileptic drug withdrawal and the implications for driving: further results from the MRC Antiepileptic Drug Withdrawal Study and a systematic review.

Laura J Bonnett1, Arif Shukralla, Catrin Tudur-Smith, Paula R Williamson, Antony G Marson.   

Abstract

BACKGROUND: In the UK, patients with epilepsy in remission, who withdraw antiepileptic drug (AED) treatment, are advised not to drive during withdrawal and for 6 months thereafter, assuming the risk of recurrence in the next 12 months is below 20%. Those with a seizure recurrence currently have to be seizure-free for 12 months before returning to drive, whether treatment is restarted or not. New EU regulations recommend returning to driving 3 months after restarting treatment.
METHODS: Regression modelling of data from the Medical Research Council AED withdrawal study was undertaken to estimate the risk of seizure recurrence in the next 12 months at various time points following: completion of drug withdrawal; AED reinstatement for those with a recurrence. A systematic review of prospective studies was also undertaken.
RESULTS: Immediately following treatment withdrawal, the recurrence risk in the next 12 months was 30% (95% CI 25% to 35%) and at 3 months after withdrawal was 15% (95% CI 10% to 19%). At 3 months following the recommencement of treatment following a seizure recurrence, the risk of a seizure in the next 12 months was 26% (95% CI 17% to 35%), at 6 months 18% (95% CI 10% to 27%) and at 12 months 17% (95% CI 3% to 27%). Systematic review results were similar.
CONCLUSION: Current UK legislation concerning time off driving after withdrawing AED treatment may be too conservative. For those restarting treatment after a recurrence, current UK guidance may be too conservative but the new EU guidance too liberal.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233143     DOI: 10.1136/jnnp.2010.222885

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  11 in total

1.  Evidence-Based Guideline: Management of an Unprovoked First Seizure in Adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Authors:  A Krumholz; S Wiebe; G S Gronseth; D S Gloss; A M Sanchez; A A Kabir; A T Liferidge; J P Martello; A M Kanner; S Shinnar; J L Hopp; J A French
Journal:  Epilepsy Curr       Date:  2015 May-Jun       Impact factor: 7.500

2.  Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Authors:  Allan Krumholz; Samuel Wiebe; Gary S Gronseth; David S Gloss; Ana M Sanchez; Arif A Kabir; Aisha T Liferidge; Justin P Martello; Andres M Kanner; Shlomo Shinnar; Jennifer L Hopp; Jacqueline A French
Journal:  Neurology       Date:  2015-04-21       Impact factor: 9.910

Review 3.  Managing an Unprovoked First Seizure in Adults.

Authors:  David S Gloss; Allan Krumholz
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

Review 4.  Practice Update: Review of Anticonvulsant Therapy.

Authors:  Derek J Chong; Andrew M Lerman
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

5.  Defining incident cases of epilepsy in administrative data.

Authors:  Paul M Bakaki; Siran M Koroukian; Leila W Jackson; Jeffrey M Albert; Kitti Kaiboriboon
Journal:  Epilepsy Res       Date:  2013-06-20       Impact factor: 3.045

6.  Profile of epilepsy in a regional hospital in Al qassim, saudi arabia.

Authors:  Nermin A Hamdy; Mohammad Jawad Alamgir; El Gamri E Mohammad; Mahmoud H Khedr; Shafat Fazili
Journal:  Int J Health Sci (Qassim)       Date:  2014-07

Review 7.  Driving and Epilepsy: a Review of Important Issues.

Authors:  Joon Y Kang; Scott Mintzer
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

8.  Risk of a seizure recurrence after a breakthrough seizure and the implications for driving: further analysis of the standard versus new antiepileptic drugs (SANAD) randomised controlled trial.

Authors:  L J Bonnett; G A Powell; C Tudur Smith; A G Marson
Journal:  BMJ Open       Date:  2017-07-10       Impact factor: 2.692

9.  The clinical value of long - term electroencephalogram (EEG) in seizure - free populations: implications from a cross-sectional study.

Authors:  Tang Xinghua; Li Lin; Fan Qinyi; Wei Yarong; Pu Zheng; Liu Zhenguo
Journal:  BMC Neurol       Date:  2020-03-12       Impact factor: 2.474

10.  Risk factors for seizure reoccurrence after withdrawal from antiepileptic drugs in individuals who have been seizure-free for over 2 years.

Authors:  XingHua Tang; Peimin Yu; Ding Ding; Yan Ge; Yunbo Shi; Ping Wang; Guoxing Zhu; Zhen Hong
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.